BVT Call 110 ABT 20.09.2024/ DE000VM3MFH1 /
2024-08-02 8:02:46 PM | Chg.+0.020 | Bid8:22:18 PM | Ask8:22:18 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.400EUR | +5.26% | 0.430 Bid Size: 107,000 |
0.440 Ask Size: 107,000 |
Abbott Laboratories | 110.00 USD | 2024-09-20 | Call |
GlobeNewswire
06-06
Circana’s 2023 New Product Pacesetters Report Reveals Innovation Is Meeting Consumers in New Moments
GlobeNewswire
05-09
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new Pre...
GlobeNewswire
03-25
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
GlobeNewswire
03-15
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt B...
GlobeNewswire
2023-11-14
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports In...
GlobeNewswire
2023-10-19
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
GlobeNewswire
2023-10-10
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
GlobeNewswire
2023-10-02
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
GlobeNewswire
2023-09-06
Endexx Corporation Appoints Ahmed Itani to Director of Marketing of HYLA in The Middle East Region